Clinical Trial Results:
Longterm efficiency and safety of intravitreal injections with bevacizumab in patients with neovascularisation or macular edema.
Summary
|
|
EudraCT number |
2013-005056-15 |
Trial protocol |
BE |
Global end of trial date |
09 Jul 2024
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
02 May 2025
|
First version publication date |
02 May 2025
|
Other versions |
|
Summary report(s) |
Final Study Report |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
AGO/2013/012
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
University Hospital Ghent
|
||
Sponsor organisation address |
C. Heymanslaan, Ghent, Belgium, 9000
|
||
Public contact |
HIRUZ, UZ Gent, 0032 93320530, hiruz.ctu@uzgent.be
|
||
Scientific contact |
HIRUZ, UZ Gent, 0032 93320530, hiruz.ctu@uzgent.be
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
15 Apr 2025
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
09 Jul 2024
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
evaluate the long-term safety and efficacy of intravitreal treatment with bevacizumab by registration of best corrected visual acuity, side-effects and central retinal thickness as measured with the ocular coherence tomography if available
|
||
Protection of trial subjects |
See attachment
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
24 Feb 2014
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Belgium: 583
|
||
Worldwide total number of subjects |
583
|
||
EEA total number of subjects |
583
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
583
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||
Recruitment
|
|||||||
Recruitment details |
See attachment | ||||||
Pre-assignment
|
|||||||
Screening details |
See attachment | ||||||
Period 1
|
|||||||
Period 1 title |
Global (overall period)
|
||||||
Is this the baseline period? |
Yes | ||||||
Allocation method |
Not applicable
|
||||||
Blinding used |
Not blinded | ||||||
Blinding implementation details |
See attachment
|
||||||
Arms
|
|||||||
Arm title
|
Global | ||||||
Arm description |
See attachment | ||||||
Arm type |
Active comparator | ||||||
Investigational medicinal product name |
Bevacizumab
|
||||||
Investigational medicinal product code |
|||||||
Other name |
|||||||
Pharmaceutical forms |
Solution for injection/infusion
|
||||||
Routes of administration |
Solution for injection
|
||||||
Dosage and administration details |
See attachment
|
||||||
|
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Global
|
||
Reporting group description |
See attachment |
|
|||||||||
End point title |
Endpoint [1] | ||||||||
End point description |
See attachment
|
||||||||
End point type |
Primary
|
||||||||
End point timeframe |
See attachment
|
||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: See attachment |
|||||||||
|
|||||||||
No statistical analyses for this end point |
|
|||
Adverse events information [1]
|
|||
Timeframe for reporting adverse events |
See attachment
|
||
Assessment type |
Systematic | ||
Dictionary used for adverse event reporting
|
|||
Dictionary name |
MedDRA | ||
Dictionary version |
0
|
||
Frequency threshold for reporting non-serious adverse events: 0% | |||
Notes [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported. Justification: See attachment |
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |